Reviewed by the Vital Signs Today editorial team. Last updated: May 2026. This article provides information only and is not a substitute for professional medical advice. See our medical disclaimer.

Key Takeaways

  • hs-CRP is a blood protein the liver releases in response to inflammation; the high-sensitivity version detects the low levels relevant to cardiovascular risk.
  • The AHA/CDC risk categories are: low (<1 mg/L), average (1 to 3 mg/L), and high (>3 mg/L).
  • A high reading does not mean heart disease is present; it signals elevated systemic inflammation, which is one risk factor among many.
  • Any acute infection, injury, or autoimmune flare will spike hs-CRP, making a single result during illness meaningless for cardiovascular assessment.
  • The 2008 JUPITER trial showed that statin therapy reduced hs-CRP by 37% and cut major cardiovascular events by 44% in people with elevated hs-CRP but normal LDL.

What Does hs-CRP Actually Measure?

High-sensitivity C-reactive protein (hs-CRP) measures the concentration of a protein your liver produces whenever your immune system signals inflammation. The short answer: it is a proxy for systemic inflammation, particularly the low-grade, chronic kind that does not cause obvious symptoms but contributes to atherosclerosis over years. What separates the hs-CRP test from a standard CRP test is detection range. Standard CRP assays read from roughly 10 to 1,000 mg/L, calibrated for diagnosing acute infections and inflammatory diseases. The high-sensitivity version reads from about 0.5 to 10 mg/L, the range where cardiovascular risk differences become detectable.

The biology is straightforward. An inflammatory stimulus, whether a bacterial infection, visceral fat accumulation, a damaged arterial wall, or autoimmune activity, prompts immune cells to release interleukin-6 (IL-6). IL-6 travels to the liver and switches on CRP gene transcription in hepatocytes, according to research published in StatPearls on the National Institutes of Health bookshelf. CRP then circulates in the bloodstream, where it can be measured. In severe acute infection, CRP concentrations can climb from under 1 microgram per mL to over 1,000 micrograms per mL within 24 to 48 hours. The levels relevant to cardiovascular assessment are far more modest, which is why the standard assay cannot see them.

One clarification that gets glossed over in most explainers: hs-CRP does not cause inflammation. It is a downstream marker. Treating the number without addressing the underlying driver changes the number but not necessarily the risk. That distinction matters when a clinician is deciding whether a statin, a lifestyle change, or further diagnostic workup is the right next step.

What Does Elevated hs-CRP Signal?

Chronically elevated hs-CRP is associated with a higher probability of heart attack, stroke, and peripheral artery disease. The association is real, consistent across large epidemiological studies, and biologically plausible: inflammation plays a direct role in plaque formation and destabilization in coronary arteries. A 2003 joint scientific statement from the American Heart Association and the CDC, published in Circulation, formalized three risk categories based on two hs-CRP measurements taken two weeks apart in otherwise healthy individuals:

  • Low cardiovascular risk: hs-CRP below 1.0 mg/L
  • Average cardiovascular risk: hs-CRP 1.0 to 3.0 mg/L
  • High cardiovascular risk: hs-CRP above 3.0 mg/L
  • Possible acute illness or other non-cardiovascular cause: hs-CRP above 10 mg/L (retest recommended)

These cutoffs have stayed remarkably stable in the two decades since. They are not thresholds for disease; they are probability gradients. A person with hs-CRP above 3 mg/L is at higher statistical risk than one below 1 mg/L, all else being equal. But all else is rarely equal in a real patient.

Where hs-CRP adds genuine value is in the intermediate-risk gray zone. A 55-year-old with borderline cholesterol, moderate blood pressure, and no family history of premature heart disease might have a 10-year cardiovascular risk score that sits right on the fence between watch-and-wait and starting a statin. An hs-CRP above 2 mg/L in that person is actionable information. The American College of Cardiology acknowledges this use case in its current lipid management guidance.

The JUPITER Trial: The Study That Changed How Cardiologists Think About hs-CRP

The most cited evidence linking hs-CRP to treatment decisions comes from the JUPITER trial, published in the New England Journal of Medicine in 2008. Researchers enrolled 17,802 men and women who had LDL cholesterol below 130 mg/dL (meaning conventional lipid guidelines would not recommend a statin) but had hs-CRP at or above 2 mg/L. Half received rosuvastatin 20 mg daily; half received placebo.

The trial was stopped early at a median follow-up of 1.9 years because the benefit was so clear. Rosuvastatin reduced the primary endpoint of major cardiovascular events by 44% compared with placebo (hazard ratio 0.56, 95% CI 0.46 to 0.69, P<0.00001). At 12 months, the statin group had 50% lower median LDL and 37% lower median hs-CRP. The trial did not prove that lowering hs-CRP was the mechanism of benefit; statins have multiple effects. But it demonstrated that elevated hs-CRP identified a population that responded strongly to statin therapy even in the absence of elevated LDL. That is not a trivial finding.

JUPITER has its critics. The trial was funded by AstraZeneca and was stopped early, which tends to inflate apparent benefit. Some cardiologists argue the absolute risk reduction was modest. Those are fair points worth holding in mind. The trial still fundamentally shifted the conversation about who might benefit from primary prevention statins, and hs-CRP sits at the center of that conversation. For a deeper look at how cholesterol markers like ApoB fit into the same risk picture, see our guide on ApoB and cholesterol.

What hs-CRP Does Not Tell You

This section is where most online health articles fall short, so let us be specific. hs-CRP is non-specific. The liver does not know whether the inflammation signal is coming from an infected tooth, an autoimmune flare, a healing knee injury, obesity-related visceral fat, or arterial wall damage. The test cannot distinguish between these sources. A 2009 paper in BMC Clinical Pathology listed conditions that confound hs-CRP interpretation: race, pulmonary disease, body mass index, sex, and osteoarthritis all affect baseline levels independently of cardiovascular disease status.

Clinically important caveats include:

  • Active infection artificially elevates the result. Testing during or immediately after any infection makes the result uninterpretable for cardiovascular purposes. Mayo Clinic Laboratories recommends against ordering hs-CRP when infection, systemic inflammation, or trauma is suspected.
  • A single test is unreliable. CRP has high intra-individual variability. The AHA/CDC statement specifically called for two measurements taken two weeks apart to establish a stable baseline.
  • hs-CRP does not localize inflammation. Knowing that CRP is elevated at 3.5 mg/L does not tell a clinician whether the source is coronary plaque, inflammatory bowel disease, gum disease, or subclinical thyroiditis. Additional workup is often needed.
  • It does not replace traditional risk factors. Blood pressure, LDL cholesterol, smoking status, family history, and diabetes status remain the foundation of cardiovascular risk assessment. hs-CRP is an add-on, not a replacement. Cleveland Clinic Laboratories describes it explicitly as a cardiovascular risk assessment aid, not a standalone diagnostic.

There is also an honest population-level limitation. Cardiovascular risk prediction models built on large datasets assign hs-CRP a relatively modest net reclassification improvement over traditional risk scores alone. It helps the most in that intermediate-risk group; it adds less value at the extremes where traditional risk factors already predict outcome clearly.

How hs-CRP Fits into a Broader Cardiovascular Workup

In practice, hs-CRP is ordered as part of a cardiovascular risk assessment, typically alongside a fasting lipid panel. When a clinician reviews both, the combination is more informative than either alone. A person with high LDL and high hs-CRP carries compounded risk from both lipid-driven and inflammation-driven pathways. A person with borderline LDL but high hs-CRP may warrant statin therapy that the lipid panel alone would not trigger. The reverse case, low hs-CRP with elevated LDL, does not eliminate cardiovascular risk; it just shifts the primary concern toward the lipid pathway.

Current U.S. cardiovascular screening guidelines assign hs-CRP a Class IIb recommendation, meaning it is reasonable to consider, with weaker supporting evidence than a Class I or IIa recommendation. The ACC’s 2025 update on cardiovascular risk reiterated that hs-CRP is a promising but not mandatory component of risk assessment. For a full picture of how inflammation and lipid markers work together, the complete guide to biomarkers covers the landscape in depth.

One practical note on lifestyle and treatment: the same interventions that lower LDL and blood pressure also lower hs-CRP. Regular aerobic exercise, a Mediterranean-style or DASH diet, weight reduction, and smoking cessation all reduce hs-CRP concentrations in controlled trials. Statins lower hs-CRP by roughly 30 to 40% independent of LDL reduction. Newer anti-inflammatory agents like colchicine have shown cardiovascular benefit in people with persistently elevated hs-CRP on statin therapy, though these are not first-line treatments and require specialist guidance.

Frequently Asked Questions

What is a normal hs-CRP level?

The American Heart Association and CDC classify hs-CRP below 1 mg/L as low cardiovascular risk, 1 to 3 mg/L as average risk, and above 3 mg/L as high risk. A result above 10 mg/L usually points to acute infection or injury rather than chronic cardiovascular inflammation, and the test should be repeated once the acute illness resolves.

Can hs-CRP diagnose heart disease?

No. hs-CRP is a risk-stratification tool, not a diagnostic test. An elevated level shows that systemic inflammation is present, which correlates with higher cardiovascular risk. It does not identify where the inflammation is coming from or confirm that atherosclerosis is present. Doctors use it alongside cholesterol panels, blood pressure, smoking history, and other markers to build a fuller risk picture.

Does high hs-CRP always mean something is seriously wrong?

Not necessarily. CRP rises sharply with any infection, physical trauma, autoimmune flare, or even vigorous exercise. A single elevated reading during or shortly after an illness is not informative for cardiovascular purposes. Most guidelines recommend confirming an elevated result with a second test two to three weeks later, in the absence of acute illness, before drawing conclusions about chronic inflammation.

Can you lower hs-CRP naturally?

Yes. Regular aerobic exercise, a diet rich in vegetables, fruits, and omega-3 fatty acids, weight loss in people with obesity, and smoking cessation all reduce hs-CRP levels in published trials. Statin medications also lower hs-CRP independently of their LDL-lowering effect, a finding central to the 2008 JUPITER trial. No supplement has shown consistent, meaningful hs-CRP reduction in high-quality studies.

Sources

  • Pearson TA, et al. Markers of inflammation and cardiovascular disease. Circulation. 2003. AHA/CDC Joint Statement. ahajournals.org
  • Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. nejm.org
  • Nehring SM, et al. C-Reactive Protein. StatPearls. National Library of Medicine. ncbi.nlm.nih.gov
  • Mayo Clinic Laboratories. HSCRP: C-Reactive Protein, High Sensitivity, Serum. mayocliniclabs.com
  • Cleveland Clinic Laboratories. High Sensitivity C-Reactive Protein. clevelandcliniclabs.com
  • Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67(6):712-723. jacc.org
  • Akula A, et al. High-sensitivity C-reactive protein in atherosclerotic cardiovascular disease: to measure or not to measure? PMC. 2025. pmc.ncbi.nlm.nih.gov

Sources